



Resource impact statement

Resource impact

Published: 1 September 2021

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended bimekizumab as an option for treating plaque psoriasis in adults, only if:

- the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
- the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated

Please see the guidance for further details.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3m people).

This is because the technology is a further treatment option and is available at a similar price.

Bimekizumab has a discount that is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

A resource impact template is provided for completion at a local level. This is because there are now several treatment options (biological and non-biological therapies) including bimekizumab that are recommended by NICE for plaque psoriasis. Organisations should complete both current and future uptake based on local practice.

This technology is commissioned by integrated care systems/clinical commissioning groups and strategic transformation partnerships. Providers are NHS hospital trusts.